In support of a relationship between aggregation and cell death, some FTDP-17 patients exhibit more aggressive symptoms than AD patients, coincident with robust tau pathology at an earlier age of onset (for review, see [96]). The gene discussed is MAPT; the disease is Alzheimer disease.